经导管主动脉瓣置换术后血栓与出血风险的平衡:JACC综述
本文为JACC综述,分析TAVR术后抗栓治疗的血栓与出血风险平衡。一方面缺血性卒中、亚临床瓣叶血栓、瓣膜血栓及长期耐久性问题提示需更强抗栓方案;另一方面该人群出血风险高且缺乏更强抗栓策略的有力证据,需谨慎。综述阐述当前现状与未来展望。
要点
- TAVR术后抗栓需在预防卒中、瓣叶血栓与出血风险间权衡
- 亚临床瓣叶血栓与瓣膜血栓是支持强化抗栓的主要担忧
- 该人群出血风险高,强化抗栓策略尚缺乏有力证据支持
核心结论
- TAVR术后最佳抗栓方案仍存争议,需在血栓风险与出血风险之间谨慎权衡。
研究设计与样本
- 综述类:分析TAVR术后抗栓治疗的理论依据,阐述当前现状与未来展望。
主要发现
- 支持强化抗栓的理由包括缺血性卒中、亚临床瓣叶血栓、瓣膜血栓及长期耐久性担忧。
- 反对强化抗栓的理由包括该人群出血风险高及缺乏支持更积极抗栓策略的有力证据。
临床怎么用
- TAVR术后抗栓决策应个体化,兼顾血栓预防需求与出血风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A large amount of evidence supports the widespread use of transcatheter aortic valve replacement (TAVR) among patients who are at low to intermediate risk for surgery. However, several controversies exist about the optimal antithrombotic regimen to use in these patients. On the one hand, concerns about ischemic stroke, subclinical leaflet thrombosis, valve thrombosis, and long-term durability suggest the need for a stronger antithrombotic regimen to ensure a better patient and valve outcome. On the other hand, the high bleeding risk of this population and the current lack of strong evidence in favor of a more aggressive antithrombotic strategy require caution. This review analyzes the rationale of antithrombotic therapy in TAVR illustrating the present scenario and future perspectives.
引用
- Mangieri A, Montalto C, Poletti E, et al. Thrombotic Versus Bleeding Risk After Transcatheter Aortic Valve Replacement: JACC Review Topic of the Week. J Am Coll Cardiol. 2019. PMID: 31623768. doi:10.1016/j.jacc.2019.08.1032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。